MCC-950 was originally found to act as a cytokine release inhibitory drug (CRID), arresting activated monocytes and preventing activation of caspase-1. Discovered to be a novel inhibitor of the NLRP3 and AIM2 inflammasomes. Blocks canonical and noncanonical NLRP3 activation at nanomolar...
Know who made it. See the evidence. Buy through one marketplace.
MCC-950 was originally found to act as a cytokine release inhibitory drug (CRID), arresting activated monocytes and preventing activation of caspase-1. Discovered to be a novel inhibitor of the NLRP3 and AIM2 inflammasomes. Blocks canonical and noncanonical NLRP3 activation at nanomolar concentrations. Inhibits interleukin 1β (IL-1β) secretion in vivo and attenuates the severity of experimental autoimmune encephalomyelitis (an MS disease model). Disrupts the interaction between AIM2 and ASC in a reconstituted cell-free inflammasome. A valuable new tool for exploring the pathophysiology of NLRP
This product is manufactured by TriBio Science and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
